Claritev Corporation (CTEV) Raises 2026 Outlook, Sees Preliminary 2027 Revenue of $1.1B

Claritev (CTEV) reported Q2 revenue of $257.5M, up 6.6%, raising full-year guidance to $1B-$1.02B. Adjusted EBITDA rose 1.1% to $155.8M, but net loss narrowed to $59.2M. Free cash flow doubled to $54.6M, yet unrestricted cash fell to $14.4M. Hedge fund ownership increased, and short interest is 9.03%.

Claritev (NYSE:CTEV) reported Q2 No Surprises Act-related revenue growth attributed mainly to one client, with management saying claim mix drove lower charges per claim. Bookings were $30M ACV in Q2 and $74M in H1, exceeding 2025 total and targeting over $100M for FY. FY revenue guidance raised to $1.00B-$1.02B and adjusted EBITDA to $610M-$620M.

Claritev Corp (CTEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. E Claritev Corporation Reports Second Quarter 2026 Results – Q2 2026 Revenues of $257.5 million grew 6.6% compared to Q2 2025 – Net Loss of $59.2 million – Adjusted EBITDA of $155.8 million increased 1.1% compared to Q2 2025 (Adjusted EBITDA Margin of 60.5% versus 63.8% in Q2 202

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

Grocery Outlet (GO) reported Q3 adjusted earnings of $0.16 per share, down from $0.21 a year earlier, with adjusted EBITDA falling to $59.4 million. The company cited promotional spending, higher supply chain costs, and increased produce shrink for the decline. GO forecasted Q4 comparable-store sales growth of 1.5% to 2.5% and adjusted earnings of $0.11 to $0.14 per share. The company plans to open 20-31 net new stores in 2027, all in existing markets.

Capricor Therapeutics reported a Q3 net loss of $42.7M, widening from $24.6M a year earlier. The company highlighted positive data on Deramiocel, its lead therapy, showing improved upper limb function in patients. Capricor is preparing for a potential launch while resolving a distribution dispute with Nippon Shinyaku. The company has sufficient cash to fund operations for at least 12 months.